CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)--Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced that research demonstrating the ...

Microarray technology has come of age as a powerful approach to revealing the genome and its dynamic expression through the application of gene-hybridization or gene-expression microarrays. While the ...

The phase 1/2 randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections that ...

Foot soldiers in the "Omics revolution" have an ally in the BioOdyssey Calligrapher MiniArrayer, a new entry into the benchtop microarray printing arena from Bio-Rad Laboratories. The $25,000 (US) ...

Multi-center Phase I clinical study will evaluate the safety and tolerability of a monovalent strain of avian influenza A (H7N9) vaccine delivered intradermally by Vaxxas’ high-density microarray ...

A study of US-based Indian and Pakistani population with cancer diagnosis reported in the SEER database from 1988 to 2002 Patients with CUP constitute approximately 5% of all malignancies and have no ...

Thermo Fisher Scientific, Inc. TMO recently launched the Applied Biosystems CytoScan HD Accel array — a new chromosomal microarray intended to enhance cytogenetic research lab productivity, efficiency ...

A Phase I/II randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections that ...

Randomised, double blind, placebo-controlled, multi-centre, group-sequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take chemotherapy No significant ...